Bit bio
VerifiedDeveloping a scalable technology platform capable of producing consistent batches of every human cell.
Launch date
Employees
Market cap
-
Net debt
-
Enterprise valuation
$412—618m (Dealroom.co estimates Nov 2021.)
Company register number 10466798
Cambridge England (HQ)
Financials
Estimates*
| EUR | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Revenues | <1m | <1m | <1m | <1m | 2.3m | <1m |
| % growth | - | 220 % | 1627 % | (56 %) | 457 % | (71 %) |
| EBITDA | - | - | (12.3m) | (33.1m) | (65.2m) | - |
| % EBITDA margin | - | - | (1327 %) | (8104 %) | (2868 %) | - |
| Profit | - | - | (13.9m) | (31.9m) | (50.2m) | - |
| % profit margin | - | - | (1500 %) | (7824 %) | (2210 %) | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | £350k | Seed | |
N/A | Support Program | ||
$41.5m | Series A | ||
$103m | Series B | ||
N/A | - | ||
| Total Funding | $145m | ||
Recent News about Bit bio
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.